PPH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PP

Volume

186.09K

Loading chart

PP

PPHVanEck Pharmaceutical ETF

PPH

Pay with—

Available Balance0.00

PP

AUM

N/A

Volume

186.09K

Yield

1.26%

Chart Earnings News About Dividends Insider Filings

Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios.Zacks Investment Research · Oct 15, 2026

Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH?The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio), higher dividends (1.9% yield), and a concentrated portfolio of 26 pharmaceutical companies with an established 15-year track record. Simplify Health Care ETF (PINK) provides broader healthcare exposure through active management of 58 positions with a unique charitable structure donating profits to cancer research, though it carries higher fees (0.51%) and lower yields (0.8%). For most long-term investors, PPH is recommended for its fundamentals, while PINK appeals to those seeking active management and charitable impact.The Motley Fool · Oct 11, 2026

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.Zacks Investment Research · Oct 5, 2026

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJPVanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).The Motley Fool · Oct 3, 2026

Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFsPresident Trump announced expanded Most-Favoured-Nation (MFN) drug pricing agreements with 26 pharmaceutical companies, covering 89% of the branded drug market. The deals include nine additional firms alongside previous agreements with major drugmakers. While lower drug prices may benefit healthcare providers and insurers, the impact on pharmaceutical companies is mixed, with agreements primarily targeting Medicaid and government-sponsored plans rather than employer-sponsored insurance.Zacks Investment Research · Sep 7, 2026

Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While XLV outperforms over 10 years, PPH delivers superior 3-year and 5-year returns. The article recommends PPH for investors seeking recent performance gains, though XLV offers better cost efficiency and diversification.The Motley Fool · Jul 26, 2026

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.The Motley Fool · Jul 9, 2026

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?VanEck Pharmaceutical ETF (PPH) offers a lower expense ratio (0.36%) and higher dividend yield (2.00%), making it ideal for income-focused investors, while Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (49.90% vs 27.10%) but has higher fees (0.57%). PPH provides global exposure with better 5-year performance, while PJP focuses exclusively on U.S. stocks and benefits from sector momentum like the GLP-1 weight loss trend.The Motley Fool · Jul 4, 2026

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?Pharmaceutical stocks experienced significant gains after the Trump administration delayed potential drug import tariffs, with major drugmakers striking deals to invest in U.S. manufacturing and avoid potential 100% tariffs.The Motley Fool · Oct 13, 2025

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign FirmsEconomist Justin Wolfers warns that proposed 100% tariffs on foreign pharmaceuticals will likely be passed onto American patients and insurers, particularly for patented brand-name drugs with inelastic demand.Benzinga · Sep 29, 2025

to start trading

PP

PPHVanEck Pharmaceutical ETF

PPH

Pay with—

Available Balance0.00

Your PositionYou don't own any PPH yet.

Related Tickers

Earnings

Dividends

Last · Oct 1Quarterly

Amount$0.36

Yield1.87%

Annual$2.14